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Abstract:   
Di-n-butyl phthalate (DBP) has been linked to the neural, reproductive and developmental 
toxicity. We present here a metabolomic study that characterized the metabolic variations 
associated with the DBP-induced teratogenesis in maternal and fetal mice. DBP at 50 and 
300 mg/kg were administrated to pregnant C57 mice, via gastric intubation on gestation day 7–9, 
respectively. Maternal mice were euthanized on gestation day 16 and examined for fetal 
development and malformations. Metabolomic study of maternal serum, placenta and fetal brain 
tissues was performed using gas chromatography time-of-flight mass spectrometry combined 
with multivariate data analysis (MVDA). The results showed that a 50 mg/kg dose of DBP had 
no significant effect on fetal development and a 300 mg/kg dose caused embryo resorption and 
fetal malformations (primarily eye abnormalities and encephalocele). MVDA indicated that DBP 
at two doses gave rise to disruption of maternal and fetal metabolic profiles characterized by 
significantly altered tricarboxylic acid cycle, amino acid, purine and lipid metabolism.  
 
Article: 
INTRODUCTION 
Di-n-butyl phthalate (DBP) is a manufactured chemical commonly used as a plasticizer and 
additive in adhesives, printing inks, and hair spray products (Premysl et al. 2005). This odorless 
and colorless synthetic chemical can readily be released to the environment, due to its lack of 
covalent bonding to other matrix materials in products (Premysl et al. 2005). As a result, DBP 
has been detected in air, drinking water, soil and food products (ATSDR 1990; Chan and Meek 
1994; IPCS 1997). Food is a primary source of human exposure to DBP and levels of DBP in 
food vary from 50 to 500 parts per billion (Kavlock et al. 2002). The acute toxicity of DBP is 
relatively low with oral LD50 values of 8–20 g/kg body weight in rats and 5–16 g/kg body 
weight in mice (IPCS 1997), however, long-term exposure to low doses of DBP in utero has 
been shown to induce serious impairment of the early reproductive (Foster et al. 2001; Gray et al. 
1982; Wine et al. 1997) and neural development (Shiota et al. 1980; Shiota and Nishimura 1982) 
in animals. Other developmental anomalies such as delayed ossification, cleft palate and so on, 
have also been observed in low-dose DBP-treated animals (Shiota et al. 1980; Shiota and 
Nishimura 1982; Ema et al. 1993). Natural exposure to food and other materials containing 
higher levels of DBP might potentially induce abnormal embryonic and fetal development and it 
has been reported that several phthalates, including DBP, detected in the urine of pregnant 
women were associated with genital defects in male infants (Swan et al. 2005).  
 
Metabolomics or metabonomics, defined as the quantitative measurement of the dynamic 
multiparametric metabolic response of living systems to pathophysiological stimuli or genetic 
modification (Nicholson et al. 1999), has been extensively used in toxicological studies, clinical 
diagnosis, drug discovery, plant science and nutrition (Premysl et al. 2005; Weckwerth et al. 
2004; Gibney et al. 2005; Um et al. 2009). Metabolomics focuses on endogenous low-molecular-
weight metabolites (generally less than 1,000 Da) and attempts to capture changes in the 
metabolic network to reveal the essence of life activities. Currently, nuclear magnetic resonance 
(NMR) and hyphenated chromatography/mass spectrometry (MS) such as gas chromatography 
or liquid chromatography coupled with mass spectrometry (GC-MS or LC-MS) (Chen et al. 
2006; Sugimoto et al. 2005; Wang et al. 2007) are the analytical platforms routinely used in 
metabolomic studies.  
 
The use of DBP is restricted or banned in cosmetics and toys in Western countries, however, 
comprehensive understanding of DBP-induced toxicity is still lacking. We therefore present a 
pilot study on neural and embryonic toxicity of DBP in a pregnant mouse model of intrauterine 
exposure with DBP using a metabolomics approach. Sera, placentas, and fetal brain tissues were 
collected from low- and high-dose DBP-treated mice as well as healthy controls. The global 
changes of metabolites in these biological matrixes of DBP-treated mice were obtained using a 
hyphenated gas chromatography/time-of-flight mass spectrometry (GC/TOFMS) in conjunction 
with multivariate data analysis (MVDA). The study identified a number of differentially 
expressed metabolites in association with the teratogenic toxicity of DBP. These metabolite 
markers collectively revealed the DBP-induced global metabolic alterations and provided 
mechanistic insights into the metabolic pathway alterations, along with neurodevelopmental 
abnormalities resulting from DBP exposure.  
 
EXPERIMENTAL METHODS 
Animal handling and sampling  
The animal study was approved by the Ethics Committee of National Research Institute for 
Family Planning (Beijing, P. R. China). Sexually mature, healthy female C57 mice (weighing 
18–22 g) were purchased from and raised in the Laboratory Animal Center, the Academy of 
Military Medical Sciences, Chinese Academy of Sciences (Beijing, P. R. China). The mice were 
housed under a controlled condition of 12 h light/12 h dark cycle at approximately 22–24°C with 
a relative humidity of 60–70%. The mice had free access to chow and water ad libitum. Each 
female mouse was mated with a sex ratio 3:1 (female:male), and gestation day (gd) 0 was 
defined by the presence of a vaginal plug or a sperm positive vaginal smear. In our preliminary 
experiments, the pregnant mice (n = 5 per group) were given 50, 300, 1,000 and 2,250 mg/kg 
DBP in olive oil (Sigma, St. Louis, MO) on gd. 7, but none of the fetuses showed apparent 
external malformations with the exception of embryo growth retardation in the 2,250 mg/kg DBP 
group. However, all of the embryos were absorbed at doses of 750 and 1,000 mg/kg DBP (n = 5 
per group) on gd. 7–9. Based on these preliminary results, the pregnant mice were randomly 
divided into three groups: two model groups with a daily dose of DBP at 50 mg/kg body weight 
(n = 12, labeled as low-dose group) and 300 mg/kg (n = 12, labeled as high-dose group) by 
gastric intubation on gd. 7–9, respectively, and a control group (n = 12) dosed with olive oil. 
Only seven mice from each group were used to provide samples for metabolomics study.  
 
All the mice were euthanized by intraperitoneal injection of pentobarbital (50 mg/kg body 
weight) at the 16th day of gestation. The blood samples were collected by enucleation of eyeball 
and the resulting sera were stored at −80°C until analysis. Placenta weight, number of 
implantation sites per litter, number of fetal resorptions per litter and number of live and dead 
fetuses per litter were recorded. The percentage of post-implantation loss per litter, live and dead 
fetuses per litter, and fetal resorptions per litter were calculated accordingly. Live fetuses and 
their brains, hearts, and livers were also weighed. All of the organs of live fetuses were examined 
for external abnormalities. All the brain or placenta tissue samples per litter were mixed as a 
single sample and stored at −80°C for metabolomic analysis.  
 
Serum sample extraction  
The extraction of serum metabolites was performed following our previously published 
procedures (Qiu et al. 2009). Briefly, each 100- µl aliquot of serum sample was added into a 1.5-
ml microcentrifuge tube. Each 10 µl of internal standards, including L-2-chlorophenylalanine 
and heptadecoic acid, were added to monitor the batch reproducibility. The tube was vortexed for 
10 s and 300 µl of a mixture of chloroform and methanol (1:3, v/v) was added for metabolite 
extraction. The resulting mixture was vortexed for 30 s and centrifuged at 10, 000 rpm for 
10 min. Each 300-µl supernatant was diverted to a glass vial for further derivatization.  
 
Tissue sample extraction  
Tissue samples (fetal brains and placentas) were extracted using our two-step extraction method 
with minor modifications (Pan et al. 2010). Internal standards, including L-2-
chlorophenylalanine and heptadecoic acid, were also added to monitor the batch reproducibility. 
Specifically, each 100 mg of tissue sample was homogenized and extracted with 500-µl solvent 
of chloroform/methanol/water (1:2:1, v/v/v). The resulting mixture was centrifuged at 10, 
000 rpm for 10 min. A 150-µl supernatant was transferred into a glass vial and the pellet was re-
extracted using 500 µl of methanol. Another 150-µl supernatant was obtained and the two 
supernatants were combined for the following derivatization.  
 
Chemical derivatization prior to GC/TOFMS Analysis  
Each 300 µl of the resulting serum or tissue extracts was dried under vacuum and reconstituted 
in 80 µl of methoxylamine hydrochloride (15 mg/ml in pyridine) for 90 min at 30°C. The 
mixture was silylated with 80 µl of N,O-bis-trimethylsilyl-trifluoroacetamide (BSTFA) 
(containing 1% trimethylchlorosilane) (Sigma, St. Louis, MO) for 1 h at 70°C. The product was 
vortexed for 10 s and kept at room temperature for 1 h. Each 1-µl aliquot of the derivatized 
product was injected at a splitless mode into an Agilent 6890N GC system coupled with a 
Pegasus HT TOFMS (Leco, St. Joseph, MI). A DB-5MS capillary column coated with 5% 
Diphenyl cross-linked 95% dimethylpolysiloxane (30 m × 250 µm i.d., 0.25-µm film thickness; 
Agilent J&W Scientific, Folsom, CA) was used. The temperature of injector, transfer line, and 
the ion source were set to 270, 260, and 200°C, respectively. Helium was used as the carrier gas 
at a constant flow rate of 1 ml/min. The initial oven temperature was set at 80°C for 2 min and 
raised up to 180°C with a rate of 10°C/min, to 230°C with a rate of 6°C/min, to 295°C with a 
rate of 40°C/min, and finally held at 295°C for 7 min. The measurements were made with 
electron impact ionization (70 eV) in the full scan mode (m/z 30–600).  
 
Data processing  
The observational data obtained from animal examinations was analyzed by one-way analysis of 
variance (ANOVA) with LSD test in SPSS 13 statistical software package (The SPSS Inc., 
Chicago, IL). A threshold of P value <0.05 was considered statistically significant.  
 
The GC/TOFMS data files were processed following our previously published procedures 
(Wang et al. 2007). The resulting data set was normalized, mean-centered, and uv-scaled (unit 
variance scaling) before multivariate statistical analysis (SIMCA-P 12.0.1, Umetrics, Umeå, 
Sweden). Principal component analysis (PCA) was initially utilized to visualize general 
clustering trends of the three groups. Based on the PCA scores plot, metabolic profiles from 
DBP-treated groups were distinct from the control group; however, PCA could not depict a clear 
separation between high-dose and low-dose groups (figure not shown). In this case, we used a 
supervised classification method partial least square- discriminant analysis (PLS-DA) to 
visualize the different metabolic profiles among the three groups. Furthermore, to identify the 
differential metabolites between each DBP-treated group versus the control group, a more 
sophisticated mathematical method, orthogonal partial least square-discriminant analysis (OPLS-
DA) was used by filtering the unrelated information from the systematic variations. Specially, 
the OPLS-DA technique (Bylesjo et al. 2006), a modification of the PLS-DA method, is able to 
divide the systematic variation of X matrix (herein, raw GC/TOFMS data set) into two parts: one 
that is linearly correlated/predictive to Y (herein, group descriptors, i.e., control group, low-dose 
group, and high-dose group) and one that is orthogonal to Y. The predictive variation of Y in X 
is modeled by the predictive components only and a single predictive component is necessary for 
two-group classification. Therefore, the OPLS-DA method provides improved model 
transparency and interpretability without compromising the power of the model prediction. For 
PLS-DA and OPLS-DA modeling in SIMCA-P software, the default sevenfold cross-validation 
procedure was carried out to avoid model overfitting and two fundamental parameters R2Y and 
Q2Y were attained accordingly. The values of R2Y and Q2Y approaching 1.0 indicate a reliable 
model with satisfactory predictability and the value of Q2Ycum ≥ 0.4 is considered a reliable 
model (www.umetrics.com). The detected metabolites with variable importance on project (VIP) 
greater than 1.0 were considered meaningful in this study (Ni et al. 2008; Qiu et al. 2010). 
Additionally, a non-parametric univariate Mann–Whitney test was used to verify whether the 
results obtained from multivariate statistics were also significant at a univariate level. The critical 
p-value of the test was set as 0.05 in this study.  
 
Metabolite identification  
We were able to identify a wide range of endogenous metabolites by comparing the spectra with 
those in NIST/EPA/NIH (NIST 05) mass spectral library (National Institute of Standards and 
Technology, Gaithersburg, MD). Subsequently, those metabolites were further verified by our 
in-house mass spectral library that was established with available reference compounds.  
 
RESULTS AND DISCUSSION 
General information about the animal experiment  
The effects of DBP on dams and embryos are shown in Table 1. In the high-dose group, there 
was a significant reduction (P < 0.01) in the number of live fetuses, together with a significant 
increase (P < 0.01) in fetal resorptions. The percentage of post-implantation loss per litter 
markedly increased to 27.48%, whereas the percentage of live fetuses per litter markedly 
decreased to 71.45%. Placenta weight was significantly reduced in high-dose groups (P < 0.01) 
as compared to the control group. 
 
Table 1: Reproductive and fetal parameters in mice treated with DBP  
  Dose (mg/kg/day) 
0 50 300 
No. of pregnant rats 12 12 12 
No. of implantation sites/litter 7.08 ± 0.56 7.50 ± 0.26 7.46 ± 0.49 
No. of resorptions/litter 0.46 ± 0.22 0.58 ± 0.26 2.05 ± 0.44** 
No. of dead fetuses/litter 0.00 ± 0.00 0.00 ± 0.00 0.08 ± 0.08 
No. of live fetuses/litter 6.62 ± 0.49 6.92 ± 0.38 5.33 ± 0.57** 
Percentage of post-implantation loss/litter 6.50 7.73 27.48 
Percentage of dead fetuses/litter 0 0 1.07 
Percentage of resorptions/litter 6.50 7.73 28.55 
Percentage of live fetuses/litter 93.50 92.27 71.45 
Placenta weight (g) 0.1188 ± 0.0047 0.1134 ± 0.0020 0.0966 ± 0.0027** 
Data are presenting as mean ± SD. ** P < 0.01 (one-way ANOVA)  
 
Table 2 also demonstrates that the weight of fetuses, fetal liver, brain and heart were 
significantly reduced in high-dose group. These were also decreased in low-dose group, but not 
significantly. No fetal malformations were observed in the low-dose group (Table 3). The overall 
percentage of fetuses with malformations was 25% of total live fetuses in the high-dose group 
and a variety of external malformations were observed in half of this group’s 12 litters (Table 3). 
The primary malformations were eye abnormalities and encephalocele. The corresponding 
histopathological images are provided in Fig. 1. 
 
Table 2: The effects of DBP on fetal development  
  Dose (mg/kg/day) 
0 50 300 
No. of fetuses 41 40 40 
Fetal body weight (g) 0.4562 ± 0.0134 0.4307 ± 0.0119 0.3615 ± 0.0158** 
Fetal brain weight (g) 0.0448 ± 0.0021 0.0407 ± 0.0016 0.0384 ± 0.0012* 
Fetal heart weight (g) 0.0059 ± 0.0006 0.0058 ± 0.0004 0.0047 ± 0.0004* 
Fetal liver weight (g) 0.0510 ± 0.0055 0.0470 ± 0.0022 0.0393 ± 0.0030** 
Data are presenting as mean ± SD. * P < 0.05, ** P < 0.01 (one-way ANOVA)  
 
Table 3: Examination for malformations  
  Dose (mg/kg/day) 
0 50 300 
Total number of fetuses (litters) examined 84 (12) 83 (12) 64 (12) 
Encephalocele 0 0 3 
Exencephaly 0 0 0 
Taillessness 0 0 1 
Eye agenesis (anophthalmos, microphthalmos or eye abnormality) 0 0 16 
Short limbs 0 0 1 
Complicated with multiple malformations  
Eye agenesis and short limbs 0 0 0 
Eye agenesis and taillessness 0 0 0 
Eye agenesis and Encephalocele 0 0 3 
Eye agenesis, taillessness and short limbs 0 0 1 
Eye agenesis, taillessness, short limbs and Encephalocele 0 0 0 
Total number of fetuses (%) with malformations 0 0 16 (25.00%) 
Total number of litters (%) with external malformations 0 0 6 (50.00%) 
 
Figure 1: Representative images of histopathological examinations on fetuses. a Normal fetal mouse. b Fetus with 
encephalocele and anopia. c Encephalocele and eye abnormities. d Anopia. e Eye abnormities. f Eye abnormities 
and anury  
 
 
Metabolic variation caused by DBP exposure  
Using a GC/TOFMS-based metabolomics approach, we were able to detect 373, 473 and 407 
chromatographic peaks from the total ion current (TIC) chromatograms of serum, placenta and 
fetal brain tissue, respectively. Each representative TIC chromatogram of serum, placenta, or 
fetal brain tissue from the control group was provided in Fig. 2a–c. As also illustrated in the 
Fig. 2d–f, there is a distinct separation between the control and DBP treatment groups, and a 
separation between the two treatment groups, as visualized in the three-dimensional PLS-DA 
scores plot. Additionally, a more distinct separation between the metabolomic profile of each 
treatment group versus the control group was observed in the OPLS-DA score plot generated 
from serum, placenta, or fetal brain tissue (Fig. 3a–f). The modeling parameters of these models 
were presented in Table 4. Based on the threshold of VIP values (VIP > 1), the differentially 
expressed metabolites in each type of biological matrix are listed in Tables 5 and 6.  
 
Figure 2: Representative TIC chromatograms of the three types of samples. a Serum. b Placenta. c Fetal brain 
tissue. Based on the retention times, the differential metabolites between each of DBP-treated groups versus the 
control group in Tables 5 and 6 can be retrieved from these representative chromatograms. Three-dimensional 
scores plot obtained from PLS-DA of global metabolites in the different types of samples among the three groups. d 
Serum. e Placenta. f Fetal brain tissue. Distinct metabolic profiles between DBP-dosed groups and control can be 
attained readily in the first PLS-DA component, and separate trend can also be observed between the two DBP-
treated groups in different PLS-DA components  
 
 
Figure 3: OPLS-DA scores plots (tP[1]/tO[1]) showing a distinct separation between each of the DBP-treated group 
versus the control group according to the metabolites from serum (a low-dose group, b high-dose group), placenta (c 
low-dose group, d high-dose group), and fetal brain tissue (e low-dose group, f high-dose group)  
Table 4: The parameters for PLS-DA and OPLS-DA models in this study  
Group 
(n = 7 
per 
group)  
Type Serum  Placenta  Fetal brain tissue 
No.a  R2Xcumb  R2Ycumc  Q2Ycumd  No. R2Xcum  R2Ycum  Q2Ycum   No. R2Xcum  R2Ycum  Q2Ycum  
High-, 
low-dose 
DBP & 
control 
PLS-
DA 
6 0.76 0.93 0.49  5 0.70 0.96 0.68  7 0.80 0.97 0.55 
Low-
dose vs. 
control 
OPLS-
DA 
1P+1O 0.47 0.94 0.57  1P+1O 0.50 0.94 0.76  1P+2O 0.56 0.95 0.67 
High-
dose vs. 
control 
OPLS-
DA 
1P+1O 0.42 0.88 0.42  1P+1O 0.49 0.98 0.86  1P+2O 0.63 0.96 0.56 
aComponents required for a valid model and prediction. For OPLS-DA, P predictive component, O orthogonal component. More details refer to the text. b R2Xcum, the cumulative 
sum of squares (SS) of the entire X explained by all extracted components. c R2Ycum, the cumulative SS of all the y-variables explained by the extracted components. d Q2Ycum, the 
cumulative Q2 for all the x-variables (PC) and y-variables (PLS) for the extracted components. The values of R2Y and Q2Y approaching 1.0 indicate a perfect model with a 
satisfactory predictive ability (cross-validation) and the value of Q2Ycum ≥ 0.4 is considered a reliable model  
 
Table 5: Differentially expressed metabolites in high-dose group versus control group  
No. RT/min Metabolite Metabolic 
pathway 
Serum  Placenta  Fetal brain tissue 
VIPb  FCc  P d   VIP FC P   VIP FC P  
1 7.35 2-Oxo-3-
methylvalerate 
Amino acid 
metabolism 
1.7 −1.8 0.0641  / / /  / / / 
2 7.59 Valinea  Amino acid 
metabolism 
1.5 −1.6 0.1320  0.2 1.2 0.5270  1.1 −1.4 0.2770 
3 8.68 Isoleucinea  Amino acid 
metabolism 
1.8 −1.8 0.0489  0.2 1.3 0.4010  1.3 −1.5 0.2010 
4 8.87 Glycine Amino acid 
metabolism 
/ / /  / / /  0.9 −1.3 0.4060 
5 11.04 Aminomalonate Amino acid 
metabolism 
1.2 −1.3 0.3540  0.7 −1.2 0.4940  0.6 1.3 0.4060 
6 11.70 Pyroglutamatea  Amino acid 
metabolism 
/ / /  / / /  1.5 2.2 0.0130 
7 11.80 γ-Aminobutyric acid Amino acid 
metabolism 
/ / /  / / /  0.4 −1.2 0.4820 
8 12.10 Creatininea  Amino acid 
metabolism 
0.7 −1.3 0.4180  1.6 2.2 0.0063  1.8 −2.0 0.0210 
9 12.90 Glutamatea  Amino acid 
metabolism 
/ / /  0.1 1.2 0.6000  1.3 −1.3 0.3370 
10 5.19 Pyruvatea  Carbohydrate 
Metabolism 
0.2 −1.0 0.9540  1.3 1.9 0.0238  1.5 1.7 0.0850 
11 5.34 Lactate Carbohydrate 
Metabolism 
1.3 1.4 0.2030  1.3 2.2 0.0087  1.5 −2.0 0.0210 
12 5.74 Glycolate Carbohydrate 
Metabolism 
1.3 1.4 0.2240  1.2 1.8 0.0460  1.3 −1.7 0.0850 
13 14.2 Ribitola  Carbohydrate 
Metabolism 
2 1.8 0.0372  0.9 1.5 0.1720  / / / 
14 14.71 Glycerol 3-
phosphatea  
Carbohydrate 
Metabolism 
1.2 1.4 0.2470  / / /  1.4 1.7 0.0850 
15 16.20 Fructosea  Carbohydrate 
Metabolism 
2.0 2.0 0.0206  0.6 1.3 0.2940  / / / 
16 17.09 D-sorbitola  Carbohydrate 
Metabolism 
/ / /  1.5 2.0 0.0157  / / / 
17 17.48 Gluconate Carbohydrate 
Metabolism 
1.7 −1.6 0.1050  1 1.6 0.1140  1.4 −1.8 0.0640 
18 19.30 Myo-inositola  Carbohydrate 
Metabolism 
0.8 −1.2 0.4880  1.5 2.2 0.0087  0.7 −1.3 0.3380 
19 9.49 Fumaratea  TCA cycle 2.2 −2.0 0.0279  0.6 1.3 0.2940  1.0 1.4 0.3060 
20 11.26 Malate TCA cycle 2.0 −2.1 0.0151  0 −1.1 0.7130  0.8 1.4 0.2250 
21 14.57 cis-aconitic acida  TCA cycle / / /  / / /  1.3 −2.1 0.0181 
22 20.98 Oleatea  Lipid metabolism 1.6 −1.5 0.1640  1.3 1.9 0.0274  0.2 1.4 0.2250 
23 21.20 Stearatea  Lipid metabolism 1.2 1.3 0.3540  1.6 2.2 0.0063  0.6 0.8 0.5650 
24 21.97 Arachidonatea  Lipid metabolism 1.3 1.4 0.2470  1.1 1.7 0.0742  0 −1.1 0.7490 
25 22.32 4-Aminohippuratea  Lipid metabolism / / /  2 −2.7 0.0011  / / / 
26 22.96 cis-5,8,11,14,17- Lipid metabolism / / /  1.7 2.6 0.0016  / / / 
eicosapentaenoic 
acid  
 
27 
 
23.72 
 
1-(9z-
Octadecenoyl)-
glycerol 
 
Lipid metabolism 
 
2.5 
 
−2.3 
 
0.0077 
  
/ 
 
/ 
 
/ 
  
/ 
 
/ 
 
/ 
28 23.92 2-(9z-
Octadecenoyl)-
glycerol 
Lipid metabolism 2.3 −2.2 0.0128  / / /  / / / 
29 24.06 1-Stearoyl-glycerola  Lipid metabolism 2.4 2.3 0.0055  1.6 2.3 0.0046  0.8 1.5 0.1800 
30 8.13 Ureaa  Purine degration / / /  1.2 2.0 0.0155  / / / 
31 11.83 Allantoina  Purine degration / / /  1.4 2.0 0.0156  / / / 
32 18.29 Xanthinea  Purine degration 2.5 2.1 0.0109  1.6 2.3 0.0046  1.3 1.4 0.1590 
33 22.32 Uridinea  Primidine 
metabolism 
/ / /  1.3 2.0 0.0180  0.4 1.1 0.7490 
aThose metabolites were verified by reference compounds available in our laboratory and the remaining metabolites were identified using commercial library database 
NIST05. b Variable importance in projection (VIP) was obtained from OPLS-DA Model. c Fold change (FC) and P values were calculated by Wilcoxon–Mann–Whitney Test. A positive 
FC value means that concentration of the metabolite is relatively higher in DBP-treated group, while a negative value suggests a relatively lower concentration in the DBP group as 
compared to the controls. “/” represents the metabolite is not detected in the biological matrix  
 
Table 6: Differentially expressed metabolites in low-dose group versus control group  
No. RT/min Metabolite Metabolic 
pathway 
Serum  Placenta  Fetal brain tissue 
VIPb  FCc  P d   VIP FC P   VIP FC P  
1 7.59 Valinea  Amino acid metabolism 2.1 −2.0 0.0209  0.6 −1.2 0.4620  1.3 −2.0 0.0212 
2 8.68 Isoleucinea  Amino acid metabolism 2.5 −2.2 0.0073  0.6 −1.3 0.3450  0.6 1.1 0.8480 
3 8.87 Glycinea  Amino acid metabolism / / /  / / /  1.4 −2.6 0.0027 
4 11.04 Aminomalonate Amino acid metabolism 2.1 −2.0 0.0157  0.4 −1.1 0.7930  0.8 1.2 0.4820 
5 11.70 Pyroglutamatea  Amino acid metabolism / / /  / / /  1.2 2.1 0.0181 
6 11.80 γ-Aminobutyric acid Amino acid metabolism / / /  / / /  1.3 −2.1 0.0181 
7 12.10 Creatininea  Amino acid metabolism 1.4 −1.7 0.0517  1.2 1.7 0.0590  1.2 −1.9 0.0331 
8 12.90 Glutamatea  Amino acid metabolism / / /  0.5 −1.3 0.3450  1.7 −2.5 0.0040 
9 5.34 Lactate Carbohydrate 
Metabolism 
0.2 1.1 0.7130  1.4 2.1 0.0120  1.7 −1.9 0.0350 
10 5.74 Glycolate Carbohydrate 
Metabolism 
2.4 2.2 0.0070  1.4 2.0 0.0160  1.9 −2.5 0.0040 
11 14.20 Ribitola  Carbohydrate 
Metabolism 
2.2 2.0 0.0160  1.4 2.0 0.0160  / / / 
12 14.71 Glycerol 3-
phosphatea  
Carbohydrate 
Metabolism 
1.2 1.5 0.1720  / / /  0.3 −1.2 0.5650 
13 17.09 D-Sorbitola  Carbohydrate 
Metabolism 
/ / /  1.5 2.0 0.0160  / / / 
14 17.48 Gluconate Carbohydrate 
Metabolism 
1.7 −1.7 0.0660  1.5 2.1 0.0100  1.4 −2.5 0.0040 
15 19.30 Myo-inositola  Carbohydrate 
Metabolism 
1.6 −1.4 0.2270  1.6 2.2 0.0060  0.6 −1.4 0.2250 
16 9.49 Fumaratea  TCA cycle 1.7 −1.6 0.1150  0.2 1.0 0.9160  0.3 −1.1 0.7010 
17 11.26 Malate TCA cycle 1.8 −1.8 0.0460  0.6 −1.4 0.2480  1.4 2.0 0.0300 
18 14.57 cis-aconitic acida  TCA cycle / / /  / / /  1.4 −2.1 0.0180 
19 20.98 Oleatea  Lipid metabolism 1.0 −1.3 0.3710  1.4 1.8 0.0356  0.3 1.5 0.1800 
20 21.20 Stearatea  Lipid metabolism 1.5 1.5 0.1720  1.4 2.1 0.0100  0.1 −1.3 0.4420 
21 21.97 Arachidonatea  Lipid metabolism 1.6 1.9 0.0274  1.1 1.7 0.0585  0.2 −1.3 0.3700 
22 22.32 4-Aminohippuratea  Lipid metabolism / / /  1.6 −2.2 0.0086  / / / 
23 22.96 cis-5,8,11,14,17-
eicosapentaenoic 
acid  
Lipid metabolism / / /  1.6 2.4 0.0033  / / / 
24 23.72 1-(9z-octadecenoyl)-
glycerol 
Lipid metabolism 2.1 −2.0 0.0157  / / /  / / / 
25 23.92 2-(9z-octadecenoyl)-
glycerol 
Lipid metabolism 2.8 −2.4 0.0033  / / /  / / / 
26 24.06 1-Stearoyl-glycerola  Lipid metabolism 2.2 2.1 0.0135  1.0 1.7 0.0585  0.3 1.2 0.5650 
27 8.13 Ureaa  Purine degration / / /  1.2 2.0 0.0155  / / / 
28 15.37 Hypoxanthinea  Purine degration / / /  / / /  1.1 1.8 0.0460 
29 18.29 Xanthinea  Purine degration 2.2 2.0 0.0160  1.3 1.9 0.0274  1.1 1.6 0.1100 
30 22.32 Uridinea  Primidine metabolism / / /  1.1 1.8 0.0357  1.3 2.0 0.0300 
aThose metabolites were verified by reference compounds available in our laboratory and the remaining metabolites were identified using commercial library database 
NIST05. b variable importance in projection (VIP) was obtained from OPLS-DA Model. c Fold change (FC) and p values were calculated by Wilcoxon–Mann–Whitney test. A 
positive FC value means that concentration of the metabolite is relatively higher in DBP-treated group, while a negative value suggests a relatively lower concentration in the 
DBP group as compared to the controls. “/” represents the metabolite is not detected in the biological matrix  
 
 
Interpretation of metabolic variations  
In our study, pregnant mice were administrated with DBP on gd. 7–9, which is the critical period 
of neural tube formation and closure, and optic vesicle formation (DeSesso et al. 1999). It 
appeared that the primary abnormalities in the experimental model groups are eye agenesis and 
encephalocele, which is consistent with the observed adverse effects on neural tube development 
due to exposure to exogenous toxicants in this special period of fetal development (DeSesso et 
al. 1999). Short limbs and taillessness were also observed as well as combination of these 
malformations.  
 
Maternal blood is the main source for fetal nutrition and the placenta is the compartment where 
the fetus exchanges nutrients and metabolites with the mother. In addition, the brain is the major 
site of embryo malformation due to DBP exposure in our study. Metabolite profiling of these 
three biological compartments can help elucidate the complex process of neural developmental 
abnormality through changes in metabolite expression and flux. In this study, we observed a 
distinct alteration of metabolite profiles in mice exposed to DBP in both dams and fetuses. The 
most significantly perturbed metabolic pathways include carbohydrate, amino acid, lipid, and 
purine metabolism, as illustrated in Fig. 4.  
 
 
 
Figure 4: The altered metabolic pathways in response to the DBP exposure. a TCA cycle and glycolysis. b 
Glutamate-related metabolism. c Purine degradation. Metabolites detected in this study are highlighted with 
grey/black color in bond italic font. More details refer to the text and Tables 5 and 6  
 
In this study, the metabolic profiles of both low and high dose DBP-treated pregnant rats and 
their fetal brain tissues are distinct from those of the controls. Significant alterations in serum 
metabolites directly reflect DBP’s impact on the pregnant rats and these metabolic alterations 
will subsequently impact the placental and fetal development. As seen in Table 1, the weight of 
the placentas in the high-dose group significantly decreased. Fumarate and malate are 
downstream metabolites of succinate in the TCA cycle (Krebs 1957). The significantly decreased 
levels of fumarate and malate in serum could be associated with mitochondrial toxicity of DBP 
due to the fact that DBP is a strong inhibitor of succinic dehydrogenase (Tanaka et al. 1978; 
Melnick and Schiller 1982). As the TCA cycle was inhibited in DBP-treated rats, anaerobic 
glycolysis could have been activated for an alternative energy supply; with the expected result of 
an enhanced level of lactate, fructose and glycerol 3-phosphate, as observed in Tables 5 and 6. 
Since anaerobic glycolysis and TCA cycle are the critical metabolic pathways for mitochondrial 
respiration (Fernie et al. 2004), the disturbance of these essential metabolites suggests an 
impaired mitochondrial respiration in DBP groups. Mitochondria are central to energy 
metabolism and cellular signaling and play fundamental roles in synthesis of nucleotides, active 
transport processes, cell motility, and cell proliferation (Rustin 2002). It has been recently 
reported that exposure to pesticide would increase the risk of Neural tube defects due to that 
many pesticides can inhibit mitochondrial oxidative phosphorylation (Rull et al. 2006). In this 
case, DBP could also cause a defective mitochondrial energy production during the process of 
fetus formation and development.  
 
Several important amino acids were altered in serum or fetal brain tissue, including isoleucine 
and its’ degradation product, 2-oxo-3-methylvalerate, and valine which decreased in the DBP-
treated pregnant rats. Isoleucine and valine belongs to essential branched-chain amino acids 
(BCAAs) that are able to convert into branched-chain α-keto acids coupled with the production 
of glutamate from α-ketoglutarate through branched-chain aminotransferase (BCAT) (Yudkoff 
1997). Since cytosolic BCAT (BCATc, one isoform of BCAT) mRNA, is strongly expressed in 
developing mouse brains (Castellano et al. 2007), the depletion of BCAAs in maternal sera may 
result in decreased BCAAs in fetuses and then may negatively impact the neurodevelopmental 
process as an insufficient nitrogen source for the synthesis of neurotransmitter glutamate. In fetal 
brain tissues, we observed significantly decreased level of valine, glutamate and γ-amino-n-
butyric acid (GABA) that are principal neurotransmitters of developmental signals in neural tube 
formation, and neuronal and glial differentiation (Lauder 1983) in low-dose group. These three 
metabolites were also reduced in high-dose group, though not significantly. The depleted level of 
glutamate and GABA in the fetal brain tissues may be strongly related to the down-regulation of 
BCAAs in the sera of their mothers.  
 
Glycine can generate glutathione (GSH), which will in turn, produce pyroglutamate in the γ-
glutamyl cycle (Meister 1974, 1995). GSH is an important intracellular antioxidant that protects 
against a variety of different oxidants. Increased pyroglutamate and decreased glycine were 
observed in the fetal brain tissue of DBP-treated groups which indicates that DBP exposure may 
induce GSH disruption. A previous study also reported that DBP can affect the antioxidant 
system of the organism and inhibit the activity of superoxide dismutase (Prasanth et al. 2009). 
We speculated that DBP could disrupt antioxidant system and may cause oxidative stress. Since 
DBP could cross the placental and fetal barrier (Saillenfait et al. 1998), the antioxidant system of 
fetuses may be disturbed by DBP that would be harmful to fetal development. Numerous reports 
suggested free radical-mediated mechanism of xenobiotics-induced abnormal embryonic 
development(DeSesso et al. 1999; Kotch et al. 1995; Dean et al. 2002).  
 
In the placentas of the DBP-treated groups, a series of metabolites of purine catabolism, such as 
xanthine, allantoin and urea significantly elevated (Tables 5, 6). The increased levels of these 
metabolites, together with the elevation of uridine, suggest an activation of nucleic acid 
degradation. DBP could give rise to DNA damage (Wellejus et al. 2002). Thus, the upregulation 
of metabolites mentioned above may be related to DNA damage caused by DBP. Superoxide 
anions are generated during the conversion of xanthine into uric acid, and that this reaction will 
aggravate lesions in the nucleic acid (Pippenger 2003).  
 
We also observed perturbations in lipid metabolism both in dam and fetus. Wyde et al. reported 
that DBP may affect lipid homeostasis (Bell 1982; Wyde et al. 2005). We observed significantly 
decreased oleate, stearate, arachidonate and cis-5,8,11,14,17-eicosapentaenoic acid in placentas. 
We suspected that DBP may inhibit the transfer of fatty acids from maternal serum and induce 
accumulation of fatty acids. Fetal development requires provision of fatty acids, especially 
essential fatty acids (Innis 2007) and disruption of fatty acid transfer may function against the 
fetal development.  
 
CONCLUDING REMARKS 
We here successfully developed malformed fetal mice model via intrauterine exposure to DBP 
during gestational days. The metabolomic profiling study of biological matrix including serum, 
placenta, and fetal brain tissue revealed a complex mechanism of teratogenesis induced by DBP 
including down-regulating of BCAAs in maternal serum that affects metabolism of 
neurotransmitters in fetal brain subsequently, disrupting of antioxidant system of the body and 
potentially inhibiting transport of fatty acids from dam to fetus. Combination of multiple sample 
matrices could provide a widened window to perceive the effect of DBP. As a result, 
characteristic metabolic variations associated with DBP induced developmental defects were 
observed including BCAAs and intermediate metabolites in TCA cycle in maternal serum, 
purine degradation products in the placenta and neurotransmitters in fetal brain tissue.  
 
ABBREVIATIONS 
DBP    Di-n-butyl phthalate  
MVDA   Multivariate data analysis 
GC/TOFMS   Gas chromatography time-of-flight mass spectrometry 
NMR    Nuclear magnetic resonance 
MS    Mass spectrometry 
GC-MS or LC-MS  Gas chromatography or liquid chromatography coupled with mass 
spectrometry 
gd    Gestation day 
One-way ANOVA  One-way analysis of variance 
PLS-DA   Partial least square-discriminant analysis 
OPLS-DA   Orthogonal partial least square-discriminant analysis 
VIP    Variable importance on project 
TIC    Total ion current 
BCAAs   Branched-chain amino acids 
BCAT   Branched-chain aminotransferase 
GABA   γ-amino-n-butyric acid  
GSH    Glutathione 
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